Here are the 10-Q quarterly reports from Monopar Therapeutics Inc. (MNPR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MNPR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MNPR filings page.
Monopar Therapeutics (MNPR) reported a third-quarter 2026 net loss of $6,196,475, compared with $3,437,601 in the 2025 quarter. For the nine months ended September 30, net loss was $15,402,825, versus $8,516,099 a year earlier. The company has generated no revenue since inception.
Cash, cash equivalents and investments totaled $129.4 million as of September 30, 2026; management estimates available funds will cover obligations at least through March 31, 2028, and determined in October 2026 there was no substantial doubt about going concern. The completed pivotal Phase 3 trial of ALXN1840 met its primary endpoint, but Alexion terminated the Wilson disease program after reviewing Phase 2 mechanistic trials and discussing results with regulatory authorities. Monopar is assembling the regulatory package and completing the rolling NDA submission, with uncertain outcomes. Other programs include MNPR-101-Zr (Phase 1) and MNPR-101-Lu (Phase 1a), plus MNPR-101-Ac (late preclinical).
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company developing ALXN1840 for Wilson disease and several radiopharmaceutical programs for advanced cancers. It remains pre-revenue and funds operations through prior equity raises, including common stock and pre-funded warrant offerings.
As of June 30, 2026, Monopar reported total assets of $134.98 million, including cash, cash equivalents and investments of $134.3 million, and total liabilities of $4.12 million. Stockholders’ equity was $130.85 million. The accumulated deficit reached approximately $98.7 million.
For the six months ended June 30, 2026, the company recorded a net loss of $9.21 million compared with $5.08 million a year earlier, driven mainly by higher research and development spending of $8.25 million versus $3.37 million. Net cash used in operating activities was $6.72 million. Management states that existing cash, cash equivalents and investments are expected to fund operations at least through December 31, 2027, and concludes there is no substantial doubt about the company’s ability to continue as a going concern within one year of issuance.
Monopar Therapeutics reported a net loss of $3.9M for the quarter ended March 31, 2026, wider than the $2.6M loss a year earlier, as it increased spending on its drug pipeline. Research and development expenses rose to $3.5M from $1.6M, while general and administrative costs were $1.7M.
The company had $137.5M in cash, cash equivalents and investments as of March 31, 2026, and management believes this will fund operations at least through December 31, 2027. Monopar remains a clinical-stage biopharmaceutical company with no product revenue, focused on ALXN1840 for Wilson disease and radiopharmaceutical programs for advanced cancers.
Monopar Therapeutics (MNPR) filed its Q3 2025 10-Q. The company ended September 30, 2025 with cash and cash equivalents of $127.7 million and investments of $16.0 million, lifting total assets to $144.2 million from $60.3 million at year-end 2024. Net loss was $3.44 million for the quarter and $8.52 million year-to-date, driven by R&D of $2.59 million and G&A of $1.50 million in Q3. Interest income contributed $655,473 in Q3 and $2.03 million year-to-date.
Monopar completed a September 2025 capital raise comprising 1,034,433 common shares at $67.67 and pre-funded warrants for 960,542 shares at $67.669, generating approximately $126.9 million in net proceeds after underwriting discounts. The company used $35.0 million to repurchase 550,229 shares at $63.6098 from Tactic Pharma. Shares outstanding were 6,662,930 at September 30, 2025 and 6,682,584 as of October 31, 2025. Management stated it has sufficient funds to meet obligations at least through December 31, 2027.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company developing ALXN1840 for Wilson disease and MNPR-101 radiopharmaceutical programs. At June 30, 2025, the company held $39,501,936 in cash and $13,748,473 in investments (about $53.3 million combined), and management estimates these funds are sufficient to fund operations at least through December 31, 2026. The balance sheet shows low total liabilities of $1.66 million and stockholders' equity of $52.2 million, with an accumulated deficit of approximately $80.9 million.
For the six months ended June 30, 2025, Monopar reported a net loss of $5,078,498 (basic and diluted net loss per share $0.73 driven by research and development of $3.37 million and general and administrative expense of $3.08 million year-to-date. Corporate developments include a transfer of IND sponsorship for ALXN1840 to Monopar effective June 6, 2025 with FDA acknowledgement on July 29, 2025. The company remains dependent on additional financing, faces milestone and royalty obligations under the Alexion license, and discloses execution risks related to regulatory review, radioisotope supply, and commercial adoption.